Emflaza Oral Suspension

  • Miscellaneous musculoskeletal disorders

Emflaza Oral Suspension Generic Name & Formulations

General Description

Deflazacort 22.75mg/mL; contains benzyl alcohol.

Pharmacological Class


See Also

How Supplied

Tabs 6mg—100; 18mg, 30mg, 36mg—30; Oral susp—13mL (w. oral dispensers)


Generic Availability


Emflaza Oral Suspension Indications


Duchenne muscular dystrophy (DMD).

Emflaza Oral Suspension Dosage and Administration

Adults and Children

<2yrs: not recommended. Use oral dispenser. Slowly add into 3–4oz of milk or juice (except grapefruit juice). ≥2yrs: 0.9mg/kg once daily. Round to the nearest tenth of a milliliter (mL). Concomitant moderate or strong CYP3A4 inhibitors: give ⅓ dose.

Emflaza Oral Suspension Contraindications

Not Applicable

Emflaza Oral Suspension Boxed Warnings

Not Applicable

Emflaza Oral Suspension Warnings/Precautions


Increased risk of infection (eg, viral, bacterial, fungal, protozoan, helminthic) and may mask signs/symptoms. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Concomitant systemic fungal infections, active ocular herpes simplex: not recommended. Hepatitis B virus reactivation. Latent or acute amebiasis. Strongyloides infestation. Cushing’s syndrome. Hyperglycemia. Thyroid disorders. Hypopituitarism. Adrenal insufficiency. Congenital adrenal hyperplasia. Pheochromocytoma. Supplement with additional steroids during physiologic stress. CHF. Hypertension. Recent MI. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Psychotic tendencies. Myasthenia gravis. Thromboembolic disorders. Risk of osteoporosis; monitor bone mineral density with long-term therapy. Administer all immunizations according to guidelines prior to initiation. Discontinue at the first sign of rash. Avoid abrupt cessation. Monitor weight, growth, BP, fluid, electrolyte balance, blood glucose, and intraocular pressure (w. therapy >6weeks). Oral susp: neonates/infants (gasping syndrome). Pregnancy. Nursing mothers.

Emflaza Oral Suspension Pharmacokinetics

See Literature

Emflaza Oral Suspension Interactions


Potentiated by moderate or strong CYP3A4 inhibitors (eg, clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice); see Adults and Children. Live or live attenuated vaccines: administer at least 4–6 weeks prior to initiation. Avoid concomitant moderate or strong CYP3A4 inducers (eg, efavirenz, carbamazepine, phenytoin). Concomitant levothyroxine: give corticosteroid first. May need to adjust dose of antidiabetic agents. Increased risk of acute myopathy with concomitant neuromuscular blockers (eg, pancuronium).

Emflaza Oral Suspension Adverse Reactions

Adverse Reactions

Cushingoid appearance, weight increase, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, nasopharyngitis; HPA axis suppression, steroid withdrawal syndrome, avascular necrosis, GI perforation, behavioral/mood changes, glaucoma, cataracts, myopathy, Kaposi's sarcoma, anaphylaxis, negative growth/development effects (in children).

Emflaza Oral Suspension Clinical Trials

See Literature

Emflaza Oral Suspension Note

Not Applicable

Emflaza Oral Suspension Patient Counseling

See Literature